Why DexCom, Inc.’s (DXCM) Stock Is Up 10.52%
As of Friday, July 31, DexCom, Inc.’s DXCM share price has surged by 10.52%, which has investors questioning if this is right time to sell.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Commentary & Analysis
Why DexCom, Inc.’s (DXCM) Stock Is Up 9.51%
As of Friday, July 31, DexCom, Inc.’s DXCM share price has surged by 9.51%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Is DexCom, Inc. (DXCM) Overvalued?
We dive into why DexCom, Inc. (DXCM) could be considered overvalued on 2026-07-17, based on AAII’s Value Score and Grade.Michael Rose
Why DexCom, Inc.’s (DXCM) Stock Is Up 6.24%
As of Thursday, July 16, DexCom, Inc.’s DXCM share price has surged by 6.24%, which has investors questioning if this is right time to sell.Michael Rose
Why DexCom, Inc.’s (DXCM) Stock Is Up 7.51%
As of Monday, June 08, DexCom, Inc.’s DXCM share price has surged by 7.51%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | DXCM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $31,490.8 | $337.2 | 90% |
|
| Shares Out (Mil) | 390.1 | 41.9 | 86% |
|
| Institutional Ownership | 99.8% | 77.8% | 94% |
|
| Float (Mil) | 384.6 | 34.7 | 83% |
|
| Beta | 1.45 | 0.85 | 81% |
|
| Avg Daily Volume (000s) | 5,011 | 278 | 92% |
|
| Price Change (52-week) |
(6.3%) | 58.7% | 40% |
|
| Growth | DXCM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.3% | 11.8% | 80% |
|
| Net Income (5yr) | 8.8% | (5.8%) | 53% |
|
| EPS (5yr) | 9.4% | 11.4% | 45 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (4.0%) | (16.3%) | 62% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 21 | 25 | 25 | |
| Current EPS | $0.673 | $2.648 | $3.111 | |
| Month Ago EPS | $0.674 | $2.587 | $3.072 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.672 | $2.571 | $3.040 | |
| Year/Year Chg | 4.7% | 26.7% | 77.0% | |
| Financials | DXCM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4,969 | $152 | 75% |
|
| Net Income (TTM) (Mil) | $1,000 | ($10) | 86% |
|
| EPS (TTM) | $2.588 | ($0.500) | 76% |
|
| Operating Cash Flow (TTM) (Mil) | $1,749 | ($2) | 87% |
|
| Net Cash Flow (TTM) (Mil) | ($55) | $1 | 19% |
|
| Long-Term Debt (Q1) (Mil) | $1,378 | $22 | 70% |
|
| Enterprise Value (Q1) (Mil) | $27,580 | $304 | 87% |
|
| Valuation | DXCM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 12.01 | 2.80 | 92% |
|
| P/E | 32.9 | 31.1 | 72% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 3.5 | 1.9 | 81% |
|
| Ratios | DXCM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 62.5% | 59.1% | 75% |
|
| Net Margin | 20.1% | (7.3%) | 79% |
|
| ROA | 14.5% | (13.7%) | 93% |
|
| ROE | 38.5% | (15.8%) | 91% |
|
| Liabilities to Assets | 59.4% | 44.7% | 53% |
|
| F-Score | 9 | 4 | 99% |
|
DexCom, Inc. did not pass any screens on 7/31/2026.
